Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYAD

Celyad (CYAD) Stock Price, News & Analysis

Celyad logo

About Celyad Stock (NASDAQ:CYAD)

Key Stats

Today's Range
$0.40
$0.65
50-Day Range
$0.59
$0.85
52-Week Range
$0.46
$3.07
Volume
3,009 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CYAD Stock News Headlines

Celyad Oncology Announces Research Facility Divestiture
Forget AI, This Will Be the Next Big Tech Breakthrough
After picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be the biggest paradigm shift ever. Yes, even bigger than AI. And he found one Seattle company that's at the center of this new $100 trillion revolution. Click here to get the name of this company, completely free of charge...tc pixel
Celyad Oncology annonce la cessation des activités R&D
See More Headlines

CYAD Stock Analysis - Frequently Asked Questions

Celyad (CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celyad investors own include Galapagos (GLPG), Cellectis (CLLS), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), bluebird bio (BLUE), Bristol Myers Squibb (BMY) and

Company Calendar

Today
10/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
N/A
Current Symbol
NASDAQ:CYAD
CIK
1637890
Employees
95
Year Founded
2007

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$200 thousand
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
30.00

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:CYAD) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners